Zacks.com on MSN18h
Why Merck (MRK) is a Top Dividend Stock for Your PortfolioGetting big returns from financial portfolios, whether through stocks, bonds, ETFs, other securities, or a combination of all, is an investor's dream. But when you're an income investor, your primary ...
Merck, the giant pharmaceutical company with multiple facilities in eastern Pennsylvania and New Jersey, isn’t too enthused about its prospects in 2025.
The drug company’s outlook for 2025 and a slide in sales of its HPV vaccine, Gardasil, hit shares.
On a per-share basis, the Rahway, New Jersey-based company said it had profit of $1.48. Earnings, adjusted for one-time gains and costs, came to $1.72 per share. The results surpassed Wall Street ...
The company's blockbuster drug Keytruda contributed $29.48 billion in sales in 2024, but the first of its patent expirations begins in 2028.
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has ...
Merck (MRK) shares drop 8% premarket as 2025 outlook falls short of Wall Street estimates, despite beating Q4 expectations ...
Merck said it expected sales of $64.1 billion to $65.5 billion in 2025 and adjusted earnings of $8.88 to $9.03 a share. Both forecasts came in below the average analyst expectation for revenue of ...
Robust evidence of the clinical benefit of WINREVAIR demonstrated in the STELLAR and ZENITH studies resulted in a loss of clinical equipoise in the HYPERION study RAHWAY, N.J., January 30 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback